Brokers Issue Forecasts for CG Oncology, Inc.’s Q1 2025 Earnings (NASDAQ:CGON)

CG Oncology, Inc. (NASDAQ:CGONFree Report) – Equities researchers at HC Wainwright issued their Q1 2025 EPS estimates for shares of CG Oncology in a report released on Friday, August 9th. HC Wainwright analyst A. Maldonado forecasts that the company will post earnings per share of ($0.46) for the quarter. HC Wainwright has a “Buy” rating and a $75.00 price target on the stock. The consensus estimate for CG Oncology’s current full-year earnings is ($1.64) per share. HC Wainwright also issued estimates for CG Oncology’s Q2 2025 earnings at ($0.48) EPS, Q3 2025 earnings at ($0.49) EPS and Q4 2025 earnings at ($0.51) EPS.

CG Oncology (NASDAQ:CGONGet Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.14. The firm had revenue of $0.11 million during the quarter.

CGON has been the topic of several other reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $75.00 target price on shares of CG Oncology in a research note on Thursday, May 2nd. The Goldman Sachs Group upgraded shares of CG Oncology from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $43.00 to $50.00 in a research note on Monday, May 13th. Finally, Bank of America began coverage on CG Oncology in a research note on Friday, June 28th. They issued a “buy” rating and a $65.00 price objective on the stock. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, CG Oncology has a consensus rating of “Buy” and a consensus price target of $64.00.

Check Out Our Latest Report on CG Oncology

CG Oncology Trading Down 2.2 %

Shares of NASDAQ:CGON opened at $32.90 on Monday. CG Oncology has a 1 year low of $25.77 and a 1 year high of $50.23. The firm’s 50-day moving average is $33.39 and its two-hundred day moving average is $36.44.

Hedge Funds Weigh In On CG Oncology

Several hedge funds have recently added to or reduced their stakes in the stock. Ameritas Investment Partners Inc. purchased a new stake in shares of CG Oncology during the 1st quarter worth approximately $102,000. California State Teachers Retirement System acquired a new stake in CG Oncology during the 1st quarter worth $103,000. Rhumbline Advisers lifted its position in CG Oncology by 13.0% in the second quarter. Rhumbline Advisers now owns 34,229 shares of the company’s stock valued at $1,081,000 after acquiring an additional 3,940 shares during the last quarter. Massachusetts Financial Services Co. MA grew its holdings in shares of CG Oncology by 2.7% during the second quarter. Massachusetts Financial Services Co. MA now owns 266,787 shares of the company’s stock worth $8,422,000 after purchasing an additional 6,899 shares during the last quarter. Finally, BNP Paribas Financial Markets purchased a new position in shares of CG Oncology during the first quarter worth about $492,000. 26.56% of the stock is currently owned by hedge funds and other institutional investors.

About CG Oncology

(Get Free Report)

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.

Recommended Stories

Earnings History and Estimates for CG Oncology (NASDAQ:CGON)

Receive News & Ratings for CG Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CG Oncology and related companies with MarketBeat.com's FREE daily email newsletter.